A Multicenter Retrospective 1-Year Observational Study Assessing Efficacy Tolerability And Conversion To Monotherapy With Eslicabazepine Acetate In Patients With Partial-Onset Seizures Who Failed On A First Line Monotherapy.

Trial Profile

A Multicenter Retrospective 1-Year Observational Study Assessing Efficacy Tolerability And Conversion To Monotherapy With Eslicabazepine Acetate In Patients With Partial-Onset Seizures Who Failed On A First Line Monotherapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies; Seizures
  • Focus Therapeutic Use
  • Acronyms EARLY-ESLI study
  • Most Recent Events

    • 06 Dec 2016 Results assessing efficacy, tolerability and conversion to monotherapy with Eslicarbazepine Acetate after first montherapy failure, presented at the 70th Annual Meeting of the American Epilepsy Society.
    • 27 Sep 2016 New trial record
    • 12 Sep 2016 Results from this study were presented at the 12th European Congress on Epileptology (ECE) 2016, according to an Eisai Co Ltd media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top